Related Experiment Video
Updated: Sep 26, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
[Arsenic trioxide in the treatment of acute promyelocytic leukaemia]
M Ercilla Liceaga1, K Andueza Granados, I Fernández González
1Servicio de Farmacia. Hospital Donostia. edificio Aránzazu. San Sebastián. Spain. afarmaci@chdo.osakidetza.net
Abstract:
Arsenic trioxide has drawn renewed interest in onco-haematological therapy. Based on a number of studies quoted in this paper, it has been approved by FDA and EMEA for remission induction and consolidation therapy of acute promyelocytic leukaemia in patients refractory to treatment using trans-retinoic acid and anthracyclines. In addition to briefly discuss available therapeutic resources against this disease, this review attempts to provide an in-depth view of this drugâs characteristics and efficacy, as shown in several studies.
Related Concept Videos
Pharmaceutical Poisoning: Treatment Strategies
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...